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A 58-year-old paraplegicmale, with long-term indwelling urethral catheter, developed catheter block.The catheter was changed, but
blood-stained urinewas drained intermittently. A long segment of the catheter was seen lying outside his penis, which indicated that
the balloon of Foley catheter had been inflated in urethra. The misplaced catheter was removed and a new catheter was inserted
correctly. Gentamicin 160mg was given intravenously; meropenem 1 gram every eight hours was prescribed; antifungals were
not given. Twenty hours later, this patient developed distension of abdomen, tachycardia, and hypotension; he was not arousable.
Computed tomography of abdomen revealed inflamed uroepithelium of right renal pelvis and ureter, 4mm lower ureteric calculus
with gas in right ureter proximally, and vesical calculus containing gas in its matrix. Urine and blood culture yielded Candida
albicans. Identical sensitivity pattern of both isolates suggested that the source of the bloodstream infection was most likely urine.
Both isolates formed consistently high levels of biofilm formation in vitro as assessed using a biofilm biomass stain, and high levels of
resistance to voriconazole were observed. Both amphotericin B and caspofungin showed good activity against the biofilms. HbA1c
was 111mmol/mol.This patient was prescribed human soluble insulin and caspofungin 70mg followed by 50mg daily intravenously.
He recovered fully from candidemia.
1. Introduction
Candidal colonisation of mucosal sites ordinarily poses no
threat to the health of the host. Problems develop when the
body’s defenses are abridged as occurs with diabetes mellitus,
human immunodeficiency virus infection, neutropenia, and
immunosuppression accompanying organ transplantation or
when patients undergo certain procedures, such as bladder
catheterisation or urologic surgery. Breaches in defense allow
increased colonisation of mucosal surfaces and sometimes
candidemia, in which case the organism can be carried to the
kidneys.These predisposing conditions permit the survival of
blood-borne or locally invasive yeast in sufficient numbers to
evade the local or systemic immunity [1].
Medical devices such as stents and catheters have been
shown to support colonisation and biofilm formation byCan-
dida spp. [2]. The Candida biofilm lifestyle results in antifun-
gal drug resistance and protection of the fungus from host
defenses [3]. Candidemia is frequently associated with the
biofilm growth of Candida organisms on medical devices
such as a venous catheter or urinary catheter. Inmice infected
with Candida albicans, degree of biofilm formation was asso-
ciated with enhanced virulence. Histology of kidney demon-
strated massive accumulation of yeast and hyphal elements
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in renal cortex, medulla, and the papilla associated with
degraded glomerulus and renal tubules in high-biofilm form-
ing Candida infectedmice. In contrast, kidney of low-biofilm
forming C. albicans infected mice showed infiltration of
fungal element and leukocytes mainly in the collecting ducts
of the papilla and only few in renal cortex and medullary
region with small inflammatory foci [4]. Indwelling urinary
catheters and stents are often associated with formation of
biofilms.C. albicans in biofilms is thought to be recalcitrant to
fluconazole, and only lipid formulation of amphotericin and
echinocandins have in vitro efficacy against Candida biofilms
[5].We reportCandida bloodstream infection following trau-
matic catheterisation in a spinal cord injury patient, who had
uncontrolled diabetes mellitus and C. albicans in urine.
2. Case Presentation
A47-year-oldBritishmale fell down aheight of 40 feet in 2002
and sustained bilateral pneumothoraces,multiple bilateral rib
fractures, andmultiple, comminuted fractures to the thoracic
spine. He developed paraplegia with sensory level of T7.
This patient required ventilator support, percutaneous, tra-
cheostomy, and percutaneous endoscopic gastrostomy. Sub-
sequently, this patient was weaned off the ventilator. He had
been managing his bladder by long-term indwelling urethral
Foley catheter.
In 2006, this patient developed erythema of right foot
with purple and necrotic areas at tips of toes and heel. In
view of irreversible ischaemia of right foot, right below knee
amputation was carried out. In 2009, computed tomography
angiogram revealed atherosclerotic changes of aorta and
lower limb arteries. There was occlusion of left superficial
femoral artery at the level of Hunter’s canal, extending down
to the trifurcation. In 2010, left above knee amputation was
performed for chronic left leg ischaemia.
In 2012, full blood count showed polycythaemia; haema-
tocrit was 0.61, haemoglobin was 19.5 g/dL, RBC was 6.35 ×
1012/L, and erythropoietin was 8.5U/L (reference range: 3.0–
18.0). This patient had chronic obstructive pulmonary dis-
ease; he was a smoker; he was treated for sleep apnoea with a
continuous positive airway pressure machine at home. Diag-
nosis was secondary polycythaemia; however, blood stud-
ies were done to rule out primary bone marrow prob-
lem. Genetic analysis for myeloproliferative disorder JAK2
p.V617F mutation in DNA was negative. With this significant
polycythaemia, one unit of venesection was performed.
Although this patient had undergone several blood tests,
glucose level or HbA1c was not tested after October 2006. In
2013, the urethral catheter was blocked and it was changed
by a community health professional at 0200 hours. Following
change of catheter, he drained urine only intermittently; the
urine was blood stained, and there was blood in the urethral
meatus as well. Therefore, this patient came to spinal unit in
the morning. On examination, a very long segment of the
catheter was lying outside the penis; this indicated that the
balloon of Foley catheter had been inflated in the urethra.The
misplaced catheter was removed, and a catheter was inserted
per urethra correctly. About 350mL of bloody urine was
drained. Gentamicin 160mgwas administered intravenously;
Figure 1: Axial section of computed tomography of abdomen and
pelvis revealed 10mm calculus in upper pole of right kidney.
meropenem 1 gram every eight hours was prescribed. No
antifungals were given to this patient. Blood tests revealed the
following: haemoglobin, was 15.1 g/dL, white cell count was
17.3, neutrophils was 16.6,HbA1cwas 111mmol/moL, C-react-
ive protein was 260.5mg/L, urea was 6.9mol/L, creatinine
was 85 umol/L.
Twenty hours after traumatic catheterisation this patient
developed distension of abdomen; heart rate increased to 125;
blood pressure decreased to 93/52mmHg; oxygen saturation
dropped to 90%; he could not be aroused to be given
medicines or nebuliser. Urine and blood cultures were taken.
In view of distended abdomen, computed tomography of
abdomen was performed. Computed Tomography revealed
the following: 10mm calculus in upper pole of right kidney
(Figure 1), a tiny calculus in the lower pole of the right kidney,
inflamed uroepithelium of right renal pelvis and right ureter
(Figure 2), 4mm calculus in lower right ureter with gas in the
lumen of right ureter proximally (Figure 3), 31mm calculus
in bladder containing gas in its matrix (Figure 4). There was
a minimal right ureteric dilatation. No calculi were seen in
the left kidney. A drainage catheter was in situ in the bladder.
Fatty changes with focal sparing were observed in the mildly
enlarged liver (Figure 5).Therewas no free gas nor fluid in the
abdomen or pelvis and no evidence of intestinal obstruction.
Umbilical and supraumbilical hernias were present. Radio-
logical evidence of (1) inflammation of right renal pelvis and
right ureter, (2) gas in the lumen of right ureter, and (3)
gas within the matrix of vesical calculus was consistent with
severe infection of urinary tract due to gas forming organism
such as Escherichia coli, Klebsiella pneumoniae, or C. albicans
[6].
Twenty-four hours later, urine microbiology report was
received, which revealed growth of >108/L of C. albicans.
Blood culture report was received forty-eight hours later;
blood culture also showed growth of C. albicans. In view of
positive blood culture, this patient was prescribed human sol-
uble insulin and caspofungin 70mg on first day followed by
50mg once daily.
Fungal isolates from blood and urine were sent to Mycol-
ogy Reference Laboratory,Wythenshawe Hospital inManch-
ester, United Kingdom, for sensitivity testing. C. albicans
isolated from urine was shown to be sensitive to flucytosine,
fluconazole, amphotericin, caspofungin, micafungin, and
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Figure 2: Axial section of computed tomography of abdomen and
pelvis revealed inflameduroepitheliumof right renal pelvis and right
ureter.
Figure 3: Coronal section of computed tomography of abdomen
and pelvis revealed inflamed uroepithelium of right renal pelvis and
gas in the lumen of right lower ureter.
anidulafungin. C. albicans grown from blood showed an
identical sensitivity pattern; the fungal isolate was sensitive
to flucytosine, fluconazole, amphotericin, caspofungin,mica-
fungin, and anidulafungin. The identical sensitivity pattern
of both isolates suggested that the source of the bloodstream
infectionwasmost likely urine. Isolates from the bloodstream
and from the catheter were tested for their ability to form
biofilms and their sensitivities were evaluated using flu-
conazole, amphotericin B, and caspofungin using established
methodologies [7, 8]. These data showed that both isolates
formed consistently high levels of biofilm formation in vitro
as assessed using a biofilm biomass stain and high levels
of resistance to voriconazole were observed (>64mg/L).
Both amphotericin B (MIC
50
= 1-2mg/L) and caspofungin
(MIC
50
= 0.25mg/L) showed good activity against the bio-
films, killing over 50% of the biofilms at these concentrations.
On the fourth day of treatment with caspofungin, blood
test revealed a rise in gamma glutamyl transferase level from
314U/L to 519U/L. Alkaline phosphatase increased from
114U/L to 293U/L. Bilirubin level increased from 6 umol/L
to 30 umol/L. Caspofungin was discontinued after six days;
this patient was then prescribed fluconazole 400mg daily by
mouth. A week later, alkaline phosphatase level decreased to
Figure 4: Axial section of computed tomography of abdomen and
pelvis: a 31mm calculus was present in bladder; the stone contained
gas in its matrix. Findings of gas within thematrix of vesical calculus
indicated that urine infection due to gas forming organisms such as
Escherichia coli orCandida albicans had been present for some time.
Figure 5: Axial section of computed tomography of abdomen
revealed mild hepatomegaly and fatty changes in liver with focal
sparing.
174U/L; gamma glutamyl transferase level also went down to
236U/L; bilirubin level diminished to 14 umol/L.
48 hours after starting caspofungin, urine showed growth
of C. albicans; blood culture taken on third day following
caspofungin therapy showed no growth; urine showed no
growth ofC. albicans on eighth day after caspofungin therapy.
This patient’s condition improved and he was discharged
home ten days after starting antifungal therapy.
This patient did not develop any new eye symptoms
such as blurring of vision or redness of eyes following this
bloodstream infection. He had watering of left eye; but this
symptom had been present for quite some time. Ophthalmic
examination revealed no evidence of endophthalmitis in both
eyes.
Following discharge, this patient was prescribed met-
formin 500mg twice a day; insulin was discontinued.
Twenty-five days after commencing treatment for diabetes
mellitus, HbA1c was 85mmol/moL; this value of HbA1c indi-
cated poor control of diabetes mellitus. Urine microbiology
revealed growth of coliform species and Enterococcus species.
Urine cytology revealed abundant mixed inflammatory cells,
bacteria, benign squamous epithelial cells, scattered, scanty
urothelial cells, and macrophages; no malignant cells were
seen.
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3. Discussion
Ang and associates defined potential risk factors for fun-
gaemia as (i) administration of antimicrobial therapy for at
least one week before the onset of fungaemia; (ii) adminis-
tration of corticosteroid therapy at the equivalent of 15mg of
prednisolone daily for at least one week; (iii) administration
of cytotoxic therapy; (iv)manipulation of urinary tract within
2 weeks of the onset of fungaemia [9].
Urologic procedures, which can predispose to fungaemia,
include open surgery, nephrostomy, cystoscopy, stent place-
ment, intermittent urinary catheterisation, and placement of
an indwelling urinary catheter. In contrast to candidemia that
arises from an intravascular focus, episodes of candiduria-
associated candidemia were of low grade and of short
duration and in many cases resolved spontaneously prior to
the institution of specific antifungal therapy. Patients with
candidemia from a urinary source had a characteristic profile:
most of them had significant anatomical urinary tract pathol-
ogy that was complicated by obstruction; these patients were
subjected to urological procedures. Although a few patients
became candidaemic within 24 hours after undergoing a uro-
logical procedure, candidemia in most patients did not occur
immediately after manipulation of urinary tract but several
days later. A plausible explanation for this course of events
includes the following factors: (1) an ascending infection
facilitated by urinary manipulation in the presence of can-
diduria; (2) subsequent development of micro- or macrofoci
of renal parenchyma infection; and (3) limited or transient
low-grade candidemia, perhaps precipitated by additional
insults. Our patient developed features of sepsis 24 hours after
traumatic catheterisation.Urine and blood cultureswere then
taken; both urine and blood cultures showed growth of Can-
dida albicans. We believe that traumatic catheterisation in the
presence of candiduria facilitated (i) an ascending urinary
tract infection, as shown by inflamed uroepithelium of right
renal pelvis and ureter, and (ii) dissemination ofCandida into
bloodstream through damaged bladder and urethral mucosa.
Liver cirrhosis has been occasionally cited as a risk factor
for fungaemia after urological procedures. Toshikuni and
associates reported a case of fungal sepsis and C. albicans
endophthalmitis after extracorporeal shock wave lithotripsy
in a cirrhotic patient [10]. Beck and associates reported two
patients with Child-Pugh class B and C liver cirrhosis who
had undergone ureteroscopy and holmium laser lithotripsy
for obstructing ureteral calculi [11]. Within 12 hours of
ureteroscopy, both patients became tachycardic, hypotensive,
and febrile. Blood, urine (proximal to the stone), and stone
cultures were positive for C. albicans in both patients. Both
patients were treated successfully with intravenous flucona-
zole. Cirrhotic patients have decreased opsonin function, an
impaired complement system, decreased antibody produc-
tion, and decreased tumour necrosis factor levels. Hassner
and associates demonstrated that monocytes of cirrhotic
patients have lower phagocytic uptake and killing of Candida
strains compared with that of controls [12]. Our patient
reported here had elevated level of gamma glutamyl trans-
ferase (314U/L; reference range: 0–50) prior to developing
fungaemia, which might be indicative of some degree of liver
dysfunction. In this patient with uncontrolled diabetes melli-
tus, computed tomography revealed mild hepatomegaly and
fatty changes in liver with focal sparing. A further increase
in gamma glutamyl transferase and a rise of alkaline phos-
phatase level (from 114U/L to 293U/L) were observed follow-
ing intravenous caspofungin therapy. caspofungin was dis-
continued and fluconazole by mouth was prescribed in order
to facilitate discharge from the hospital. Fluconazole was less
expensive than caspofungin and high cost of caspofungin
could not be ignored. However, it should be remembered that
Fluconazole therapy can result in liver toxicity, which ranges
from mild and transient enzyme elevations to clinically
apparent hepatitis to acute liver failure and death. The cause
of clinically apparent hepatotoxicity from fluconazole is
unknown; however, it may relate to the ability of fluconazole
to alter sterol synthesis. Fluconazole is a potent inhibitor of
the cytochrome P450 enzyme CYP3A4 and can lead to sig-
nificant increases in plasma levels and serious toxicity from
medications that are ordinarily metabolized by CYP3A4,
particularly the statins and cyclosporine [13].
Microbial biofilms develop when organisms adhere to a
surface and produce extracellular polymers that provide a
structural matrix and facilitate further adhesion [3, 5, 14].
Organisms in biofilms behave differently from freely sus-
pendedmicrobes and have been shown to be relatively refrac-
tory to medical therapy. C. albicans biofilm formation has
three developmental phases: adherence of yeast cells to the
device surface (early phase), formation of a matrix with
dimorphic switching from yeast to hyphal forms (interme-
diate phase), and increase in the matrix material taking on a
three-dimensional architecture (maturation phase) [15]. Fully
mature Candida biofilms have a mixture of morphological
forms and consist of a dense network of yeasts, hyphae, and
pseudohyphae in a matrix of polysaccharides, carbohydrate,
protein, and unknown components [14]. The formation and
structure of these biofilms are influenced by the nature of the
contact surface, environmental factors, morphogenesis, and
the Candida species involved.
Tumbarello and associates identified two unique risk
factors, diabetes mellitus and urinary catheterisation, which
were specifically associated with biofilm-forming Candida
bloodstream infection [5]. Candidemia is frequently associ-
ated with the biofilm growth of Candida organisms on med-
ical devices such as a venous catheter or urinary catheter [2].
Such infection is serious because biofilms are thought to be
recalcitrant to antifungals, for example, fluconazole, while
only two classes of agents (i.e., liposomal amphotericin B and
echinocandins) appear to have in vitro efficacy against Can-
dida [16].
Tumbarello and colleagues reported that clinical isolates
from Candida bloodstream infections that formed biofilms
displayed greater levels of morbidity and mortality [17].
Therefore, it may be prudent to test and establish whether or
not clinical isolates of Candida from selected patients form
biofilms: for example, those who develop Candida blood-
stream infection associated with a central venous line or
a peripherally inserted central catheter, implanted medi-
cal devices such as joint prostheses, or indwelling urinary
catheter. If biofilm formation is detected, such a patient will
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require appropriate antifungal therapy. Kojic and Darouiche
reported that C. albicans in biofilms on polyvinyl chloride
disks is 30 to 2,000 times more resistant to fluconazole,
amphotericin B, flucytosine, itraconazole, and ketoconazole
than planktonic cells [18], and the biofilm structure remained
intact at an amphotericin B concentration of 11 times themin-
imum inhibitory concentration. However, both echinocan-
dins and liposomal formulations of amphotericin B have
been shown to be effective against C. albicans biofilms [16,
19, 20]. Suggested mechanisms of biofilm resistance include
restricted penetration of drugs through the matrix, slow
growth of organisms in biofilms accompanied by changes in
the cell surface composition affecting their susceptibility to
drugs, and unique biofilm-associated patterns of gene expres-
sion [14].
Toshikuni and associates suggested that administra-
tion of antifungal agents before extracorporeal shock wave
lithotripsy might be helpful for preventing fungaemia in
patients with funguria [10]. The mechanical trauma to the
ureter during extracorporeal shock wave lithotripsy might
result in dissemination of C. albicans into the bloodstream
from urine, infected stent, or urinary calculi. It appears rea-
sonable to extend this concept of administering antifungals to
spinal cord injury patients with candiduria, in whomurethral
catheterisation proves traumatic, as indeed happened to our
patient.
4. Learning Points from This Case
(i) Antifungal therapy with echinocandins or lipid for-
mulation of amphotericin B should be administered
after traumatic catheterisation in a spinal cord injury
patient with uncontrolled diabetes mellitus and C.
albicans in urine.
(ii) Fungal isolates may be tested for biofilm formation
capacity, as infection with biofilm-forming Candida
species is recalcitrant to fluconazole; only lipid formu-
lation of amphotericin B and echinocandins appear to
have in vitro efficacy against Candida biofilms.
(iii) Persons with spinal cord injury are at increased risk
for developing diabetes mellitus. This patient was not
tested for diabetes mellitus during the past twelve
months although he visited the hospital several times.
This case is a reminder that spinal injury patients
require global assessment instead of fragmented care
focusing on just one aspect such as management of
respiratory tract or pressure sores.
(iv) In this patient, who had raised gamma glutamyl
transferase and alkaline phosphatase, fluconazole was
prescribed to facilitate discharge home. Spinal cord
physicians should remember that fluconazole therapy
can result in liver toxicity, which ranges from mild
and transient enzyme elevations to clinically apparent
hepatitis to acute liver failure and death.
(v) Computed tomography of urinary tract proved to be a
valuable investigation in this patient. CT revealed evi-
dence of inflammation of right renal pelvis and ureter
and gas in right ureter and in the matrix of vesical
calculus.
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